Tailoring antidepressant therapy based on genetic profiles: Review

Yosef Houmid Al Shammari; Homoud Awade Al Shammari; Talal Muhammad bin Barak; Bandar Said Alharbi; Saud Tawfiq Alshammari; Saleh Abdullah Alnais; Saeed Awad Aljohani; Abdulrahman Abdullah Alorf; Meshari Abdulmajeed Alnawmasi; Mohammed Awad Alshammari; Majed Farhan Alharbi; Abdulrahman Gobile Al Enazi; Abdulelah Mohammed Mubashir Alamri

doi:10.53730/ijhs.v2nS1.14915

Authors

Yosef Houmid Al Shammari KSA, National Guard Health Affairs
Homoud Awade Al Shammari KSA, National Guard Health Affairs
Talal Muhammad bin Barak KSA, National Guard Health Affairs
Bandar Said Alharbi KSA, National Guard Health Affairs
Saud Tawfiq Alshammari KSA, National Guard Health Affairs
Saleh Abdullah Alnais KSA, National Guard Health Affairs
Saeed Awad Aljohani KSA, National Guard Health Affairs
Abdulrahman Abdullah Alorf KSA, National Guard Health Affairs
Meshari Abdulmajeed Alnawmasi KSA, National Guard Health Affairs
Mohammed Awad Alshammari KSA, National Guard Health Affairs
Majed Farhan Alharbi KSA, National Guard Health Affairs
Abdulrahman Gobile Al Enazi KSA, National Guard Health Affairs
Abdulelah Mohammed Mubashir Alamri KSA, National Guard Health Affairs

Keywords:

Major depressive illness, Antidepressant drugs, Genetics, Precision medicine

Abstract

Background: Depression is a substantial public health concern that impacts millions of individuals globally. The wide range of symptoms and manifestations of depression emphasizes the need of tailoring treatment methods to each individual, which includes adapting antidepressant prescriptions accordingly. Genetic factors contribute to depression and its association with other psychiatric and non-psychiatric illnesses, highlighting the need of a thorough assessment that encompasses psychopathology, physical health, and genetic variables. Aim of Work: This research aims to highlight the significance of customized therapy in the management of depression, taking into account hereditary variables, metabolic abnormalities, and inflammatory indicators. The research also seeks to emphasize the potential use of genotyping in directing the selection of antidepressants and making dose changes for people with altered metabolism. Methods: The research entails examining previously published works on the genetic factors related to depression, the influence of inflammatory and metabolic abnormalities in its development, and the possible advantages of genotyping in the treatment of antidepressants. The research also examines the incorporation of genetic information, such as the tendency to develop cardio-metabolic illnesses due to several genes, together with non-genetic risk factors to improve treatment results.

Downloads

Download data is not yet available.

References

World Health Organization, author. Depression and other common mental disorders: global health estimates [Internet] World Health Organization; Geneva: 2017.

Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, et al. CANMAT Depression Work Group, author. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can J Psychiatry. 2016;61:540–560.

Huynh NN, McIntyre RS. What are the implications of the STAR*D trial for primary care? A review and synthesis. Prim Care Companion J Clin Psychiatry. 2008;10:91–96.

Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60:1439–1445.

Serretti A. The present and future of precision medicine in psychiatry: focus on clinical psychopharmacology of antide-pressants. Clin Psychopharmacol Neurosci. 2018;16:1–6.

Pain O, Hodgson K, Trubetskoy V, Baune B, Biernacka J, Fabbri C, et al. Investigating the common genetic basis of antidepressant response. Abstract NR 57; 27th World Congress of Psychiatric Genetics (WCPG); Oct 26-31, 2019; Los Angeles, USA. pp. S91–S92.

Badini I, Coleman JRI, Hagenaars SP, Hotopf M, Breen G, Lewis CM, et al. Depression with atypical neurovegetative symptoms shares genetic predisposition with immuno-metabolic traits and alcohol consumption. Psychol Med. 2020

Milaneschi Y, Lamers F, Peyrot WJ, Baune BT, Breen G, Dehghan A, et al. CHARGE Inflammation Working Group and the Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, author. Genetic association of major depression with atypical features and obesity-related immunometabolic dysregulations. JAMA Psychiatry. 2017;74:1214–1225.

Milaneschi Y, Lamers F, Peyrot WJ, Abdellaoui A, Willemsen G, Hottenga JJ, et al. Polygenic dissection of major depression clinical heterogeneity. Mol Psychiatry. 2016;21:516–522.

International Society of Psychiatric Genetics, author. Genetic Testing Statement [Internet] International Society of Psychiatric Genetics; Brentwood (TN): 2019.

Chatzou M. The ultimate guide on how to offer genetic testing services or boost your current offerings in no time [Internet] Lifebit Blog; London: 2019. [cited 2020 Jul 21].

Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 13th ed. Wiley-Blackwell; Hoboken: 2018.

Nihalani N, Schwartz TL, Siddiqui UA, Megna JL. Weight gain, obesity, and psychotropic prescribing. J Obes. 2011;2011:893629.

Tyrrell J, Mulugeta A, Wood AR, Zhou A, Beaumont RN, Tuke MA, et al. Using genetics to understand the causal influence of higher BMI on depression. Int J Epidemiol. 2019;48:834–848.

Rizvi SJ, Grima E, Tan M, Rotzinger S, Lin P, Mcintyre RS, et al. Treatment-resistant depression in primary care across Canada. Can J Psychiatry. 2014;59:349–357.

Kemp DE, Schinagle M, Gao K, Conroy C, Ganocy SJ, Ismail-Beigi F, et al. PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression. CNS Drugs. 2014;28:571–581.

Colle R, de Larminat D, Rotenberg S, Hozer F, Hardy P, Verstuyft C, et al. PPAR-γ agonists for the treatment of major depression: a review. Pharmacopsychiatry. 2017;50:49–55.

Köhler-Forsberg O, Gasse C, Berk M, Østergaard SD. Do statins have antidepressant effects? CNS Drugs. 2017;31:335–343.

Chamberlain SR, Cavanagh J, de Boer P, Mondelli V, Jones DNC, Drevets WC, et al. Treatment-resistant depression and peripheral C-reactive protein. Br J Psychiatry. 2019;214:11–19.

Jha MK, Minhajuddin A, Gadad BS, Greer T, Grannemann B, Soyombo A, et al. Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. Psychoneuroendocrinology. 2017;78:105–113.

Jha MK, Trivedi MH. Personalized antidepressant selection and pathway to novel treatments: clinical utility of targeting inflammation. Int J Mol Sci. 2018;19:233.

Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31–41.

Perna G, Alciati A, Daccò S, Grassi M, Caldirola D. Personalized psychiatry and depression: the role of sociodemographic and clinical variables. Psychiatry Investig. 2020;17:193–206.

Ward J, Lyall LM, Bethlehem RAI, Ferguson A, Strawbridge RJ, Lyall DM, et al. Novel genome-wide associations for anhedonia, genetic correlation with psychiatric disorders, and polygenic association with brain structure. Transl Psychiatry. 2019;9:327.

Thorp JG, Marees AT, Ong JS, An J, MacGregor S, Derks EM. Genetic heterogeneity in self-reported depressive symptoms identified through genetic analyses of the PHQ-9. Psychol Med. 2019 doi: 10.1017/S0033291719002526.

Fanelli G, Benedetti F, Kasper S, Kautzky A, Zohar J, Souery D, et al. Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder. [cited 2020 Jul 21];medRxiv.2020.01.15.20017699 [Preprint] 2020

DeVido JJ, Weiss RD. Treatment of the depressed alcoholic patient. Curr Psychiatry Rep. 2012;14:610–618.

Marmorstein NR. Associations between subtypes of major depressive episodes and substance use disorders. Psychiatry Res. 2011;186:248–253.

Leventhal AM, Francione Witt C, Zimmerman M. Associa-tions between depression subtypes and substance use dis-orders. Psychiatry Res. 2008;161:43–50.

Brailean A, Curtis J, Davis K, Dregan A, Hotopf M. Characteristics, comorbidities, and correlates of atypical depression: evidence from the UK Biobank Mental Health Survey. Psychol Med. 2020;50:1129–1138.

Kranzler HR, Zhou H, Kember RL, Vickers Smith R, Justice AC, Damrauer S, et al. Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. Nat Commun. 2019;10:1499.

PharmGKB, author. Clinical guideline annotations [Internet] PharmGKB; Stanford (CA): 2020. [cited 2020 Jul 21].

Porcelli S, Fabbri C, Spina E, Serretti A, De Ronchi D. Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Expert Opin Drug Metab Toxicol. 2011;7:1101–1115.

Fabbri C, Tansey KE, Perlis RH, Hauser J, Henigsberg N, Maier W, et al. Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: meta-analysis of data from genome-wide association studies. Eur Neuropsycho-pharmacol. 2018;28:945–954.

Howland RH. A critical evaluation of the cardiac toxicity of citalopram: part 1. J Psychosoc Nurs Ment Health Serv. 2011;49:13–16.

Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019;111:59–67.

Picard N, Boyer JC, Etienne-Grimaldi MC, Barin-Le Guellec C, Thomas F, Loriot MA French National Network of Pharmaco-genetics (RNPGx), author Pharmacogenetics-based personalized therapy: levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx) Therapie. 2017;72:185–192.

Maruf AA, Fan M, Arnold PD, Müller DJ, Aitchison KJ, Bousman CA. Pharmacogenetic testing options relevant to psychiatry in Canada: options de tests pharmacogénétiques pertinents en psychiatrie au Canada. Can J Psychiatry. 2020;65:521–530.

Fabbri C, Zohar J, Serretti A. Pharmacogenetic tests to guide drug treatment in depression: comparison of the available testing kits and clinical trials. Prog Neuropsychopharmacol Biol Psychiatry. 2018;86:36–44.

Bousman C, Maruf AA, Müller DJ. Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel. Curr Opin Psychiatry. 2019;32:7–15.

So HC, Sham PC. Exploring the predictive power of polygenic scores derived from genome-wide association studies: a study of 10 complex traits. Bioinformatics. 2017;33:886–892.

Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome Med. 2020;12:44.

Lambert SA, Abraham G, Inouye M. Towards clinical utility of polygenic risk scores. Hum Mol Genet. 2019;28:R133–R142.

Wu Q, Kling JM. Depression and the risk of myocardial infarction and coronary death: a meta-analysis of prospective cohort studies. Medicine (Baltimore) 2016;95:e2815.

Holt RI, de Groot M, Golden SH. Diabetes and depression. Curr Diab Rep. 2014;14:491.

Läll K, Mägi R, Morris A, Metspalu A, Fischer K. Personalized risk prediction for type 2 diabetes: the potential of genetic risk scores. Genet Med. 2017;19:322–329.

García-González J, Tansey KE, Hauser J, Henigsberg N, Maier W, Mors O, et al. Pharmacogenetics of antidepressant response: a polygenic approach. Prog Neuropsychopharmacol Biol Psychiatry. 2017;75:128–134.

Amare AT, Schubert KO, Hou L, Clark SR, Papiol S, et al. International Consortium on Lithium Genetics (ConLi+Gen), author Association of polygenic score for schizophrenia and HLA antigen and inflammation genes with response to lithium in bipolar affective disorder: a genome-wide association study. JAMA Psychiatry. 2018;75:65–74.

Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, author. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018;50:668–681.

Lambert SA, Gil L, Jupp S, Ritchie SC, Xu Y, Buniello A, et al. The polygenic score catalog: an open database for reproducibility and systematic evaluation. [cited 2020 Jul 21];medRxiv. 2020.05.20.2010821 [Preprint] 2020

Folkersen L, Pain O, Ingason A, Werge T, Lewis CM, Austin J. Impute.me: an open-source, non-profit tool for using data from direct-to-consumer genetic testing to calculate and interpret polygenic risk scores. Front Genet. 2020;11:578.